Placebo-Controlled Comparison of Three Dose-Regimens of 5-Hydroxytryptophan Challenge Test in Healthy Volunteers

@article{Gijsman2002PlaceboControlledCO,
  title={Placebo-Controlled Comparison of Three Dose-Regimens of 5-Hydroxytryptophan Challenge Test in Healthy Volunteers},
  author={Harm J. Gijsman and Joop M A van Gerven and Marieke L. de Kam and Rik Schoemaker and Monique S M Pieters and Margo Weemaes and Roel de Rijk and J.P. van der Post and Adam F Cohen},
  journal={Journal of Clinical Psychopharmacology},
  year={2002},
  volume={22},
  pages={183-189}
}
Single-dose administration of 5-hydroxytryptophan (5-HTP) is regularly used as a challenge test of the serotonergic system. The use of 5-HTP has been limited by an apparent small window between the occurrence of neuroendocrine endpoints and the occurrence of side effects. Therefore, many dosing strategies have been tried with and without concurrent administration of carbidopa, a peripheral inhibitor of the decarboxylation from 5-HTP to serotonin. The aim of the current study was to assess the… Expand
Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa
TLDR
Orally administered 5-HTP combined with CBD is an effective serotonergic challenge test, exhibiting dose-related plasma concentrations and neuroendocrine responsiveness, but frequent occurrence of nausea and vomiting limits the applicability of this challenge at 5- HTP doses above 100mg. Expand
Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron
TLDR
Addition of granisetron to the combined 5-HTP/CBD challenge suppresses nausea and vomiting without influencing the neuroendocrine response or pharmacokinetics, enhancing its clinical applicability in future psychiatric research and drug development. Expand
Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat
TLDR
5-HTP/30 mg/kg carbidopa potentiates the anorectic effect of diethylpropion and phentermine with an acceptable safety profile, but further clinical studies are necessary to establish their therapeutic potential in the obesity treatment. Expand
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding
TLDR
Preliminary evidence of clinical benefit of 5-HTP against LIDs in PD is provided, and larger studies with a longer treatment duration and a wider range of doses are warranted to corroborate these findings. Expand
The Triple Combination Phentermine Plus 5-HTP/Carbidopa Leads to Greater Weight Loss, With Fewer Psychomotor Side Effects Than Each Drug Alone
TLDR
It is found that the triple-drug combination leads to greater weight-loss than each drug alone, and as the treatment progresses, the triple drug combination partially reversed psychomotor side-effects induced by Phen. Expand
Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.
TLDR
Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind, placebo-controlled (DB-PC) trials, and safety issues with 5- HTP are reviewed,With emphasis on eosinophilia myalgia syndrome (EMS) and serotonin syndrome. Expand
Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept
TLDR
Preclinical data suggest that 5-HTP SR could represent a new therapeutic approach to the plethora of CNS disorders potentially treatable with a pro-serotonergic drug, and might in particular be therapeutically relevant when brain 5- HT deficiency is pathogenic and as an adjunctive augmentation therapy to SSRI therapy. Expand
Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.
TLDR
Adjunctive administration of 5-hydroxytryptophan SR safely elevates 5-HTExt beyond the SERT inhibitor effect in humans; however,5-HTP cannot be a clinically viable drug because of its poor pharmacokinetics. Expand
l-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI
TLDR
The results of the study suggest that an augmented neuroendocrine challenge may be a suitable marker to demonstrate increased 5-HT-mediated responses when exploring novel agents as improved SSRIs. Expand
SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept
TLDR
The hypothesis that slow-release drug delivery will substantially improve 5-HTP’s drug properties is tested, by minimizing adverse effects and securing sustained 5- HTExt elevation beyond the SSRI effect, to suggest a novel treatment for TRD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
TLDR
The ratio of 5-HTP to carbidopa influenced the systemic bioavailability of single dose administered 5-hydroxytryptophan indicating dose dependent absorption kinetics, and co-administration of L-dopa with 5- HTP and decarboxylase inhibitors had no effect on gastrointestinal absorption in six parkinsonian patients. Expand
Kinetics of l-5-hydroxytryptophan in healthy subjects
TLDR
The kinetics of l-5-hydroxytryptophan were studied in five volunteers after intravenous and oral administration of 5-HTP following pretreatment with carbidopa, and Gastrointestinal side effects appeared to be related to the 5- HTP plasma concentration. Expand
Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder
To investigate the role of serotonin (5-HT) in the pathophysiology of panic disorder (PD) a challenge test with L-5-hydroxytryptophan (5-HTP) was conducted. Seven patients suffering from PD and sevenExpand
Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers.
TLDR
It is doubtful whether mCPP is a useful compound for challenge tests in view of the large pharmacokinetic variability after intravenous and oral administration, and the effects of m CPP are consistent with disinhibition of the central nervous system. Expand
Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man.
TLDR
The pharmacokinetics of 5-hydroxytryptophan were investigated in relation to intravenous administration of single doses of the amino acids to five patients pretreated for one week with carbidopa, an L-aromatic amino acid decarboxylase inhibitor and the data obtained could be closely fitted to an open two compartment pharmacokinetic model. Expand
Effect of 5-hydroxy-l-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis
TLDR
It is demonstrated that systemic administration of 5-HTP caused an increase in the release of 5,HT in the hypothalamus, which occurred by a calcium-dependent mechanism (probably exocytosis), was dependent on serotoninergic neuronal activity and predominantly derived from 5- HT neurones. Expand
The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.
5-Hydroxytryptophan has been found to be beneficial when administered alone or in combination with extracerebral aromatic amino acid decarboxylase inhibitors for therapeutic purposes in variousExpand
Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder
TLDR
Plasma melatonin increased significantly after 5HTP administration, suggesting that increasing 5HT availability in man might affect melatonin synthesis, and the results are at odds with the hypothesis that there is a supersensitivity of 5HT2 receptors in panic disorder. Expand
Brain 5-HT neurotransmission during paroxetine treatment.
TLDR
SSRI treatment in depressed patients produces a persistent increase in the cortisol response to 5-HTP, a probable measure of neurotransmission at central5-HT2 receptors, which might underlie their actions in obsessive-compulsive disorder and also perhaps certain of their adverse effects, notably sexual dysfunction. Expand
Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors.
TLDR
The results suggest that the prolactin and ACTH responses to 5-HTP in the male rat are mediated by 5-hydroxy-L-tryptophan-like receptors, similar to that of the female rat. Expand
...
1
2
3
...